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Background
The goal of this study was to evaluate the effectiveness of
amisoulpride (Solian) in chronic alcoholic patients and
the registration of decrement of tendency to drink alco-
hol.
Materials and methods
33 patients (28 males and 5 females) who voluntarily
came to the outpatient psychiatric department of our hos-
pital with the request to break off abuse of alcohol were
studied. Amisoulpride was given at dose 800 mg to all
patients as the only treatment with gradual increase to
1200 mg. Our study involved patients with abuse of alco-
hol for longer than 2 years, aged 20-60 years. Patients with
serious somatic problems (diabetes mellitus, chronic
renal failure, liver disorder) were exempted. The effective-
ness was evaluated after 1, 6 and 12 months of treatment.
Results
Treatment with amisoulpride at dose 800 mg ?24h
reduces significant the tendency of alcohol drinking in
most of patients and that became more obvious 3 months
later. The dose increased to 1200 mg for 8 patients
because the results after 3 months of treatment were not
significant. After 12 months of treatment, 29 patients cut
off the abuse of alcohol and only 4 patients quit the treat-
ment.
Conclusions
Administration of amisoulpride at dose 800-1200 mg to
chronic alcoholic patients for 12 months causes gradual
reduction of tedency to alcohol drinking.
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